Our goal is to untap the potential of peptide biology to create the next generation of medicines through precision engineering and design. Through this effort, we intend to cure and prevent devastating and costly medical device-related infections for millions of people each year.
Peptilogics is ushering in a new era of engineered peptide therapeutics to restore mobility and hope for millions of people worldwide.
Peptilogics’ clinical stage pipeline is led by PLG0206, a novel engineered peptide, currently enrolling the pivotal Ph2b/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status.